Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Significant hearing loss in Fabry disease : Study of the Danish nationwide cohort prior to treatment. / Yazdanfard, Puriya Daniel; Madsen, Christoffer Valdorff; Nielsen, Lars Holme; Rasmussen, Åse Krogh; Petersen, Jørgen Holm; Seth, Alka; Sørensen, Søren Schwartz; Køber, Lars; Feldt-Rasmussen, Ulla.

I: PLoS ONE, Bind 14, Nr. 12, e0225071, 12.2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Yazdanfard, PD, Madsen, CV, Nielsen, LH, Rasmussen, ÅK, Petersen, JH, Seth, A, Sørensen, SS, Køber, L & Feldt-Rasmussen, U 2019, 'Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment', PLoS ONE, bind 14, nr. 12, e0225071. https://doi.org/10.1371/journal.pone.0225071

APA

Yazdanfard, P. D., Madsen, C. V., Nielsen, L. H., Rasmussen, Å. K., Petersen, J. H., Seth, A., Sørensen, S. S., Køber, L., & Feldt-Rasmussen, U. (2019). Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment. PLoS ONE, 14(12), [e0225071]. https://doi.org/10.1371/journal.pone.0225071

Vancouver

Yazdanfard PD, Madsen CV, Nielsen LH, Rasmussen ÅK, Petersen JH, Seth A o.a. Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment. PLoS ONE. 2019 dec.;14(12). e0225071. https://doi.org/10.1371/journal.pone.0225071

Author

Yazdanfard, Puriya Daniel ; Madsen, Christoffer Valdorff ; Nielsen, Lars Holme ; Rasmussen, Åse Krogh ; Petersen, Jørgen Holm ; Seth, Alka ; Sørensen, Søren Schwartz ; Køber, Lars ; Feldt-Rasmussen, Ulla. / Significant hearing loss in Fabry disease : Study of the Danish nationwide cohort prior to treatment. I: PLoS ONE. 2019 ; Bind 14, Nr. 12.

Bibtex

@article{7896b83a4387492192e551acf2affce6,
title = "Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment",
abstract = "Background Fabry disease (FD) is a lysosomal storage disorder resulting in systemic accumulation of globotriaosylceramide resulting in multi-organ dysfunction e.g. cerebral, cardiac, renal and audiologic complications. The audiologic involvement in FD has often been neglected; while not a lethal aspect of the disease, hearing loss can have a significantly negative impact on quality of life. Objectives To investigate baseline hearing status of the Danish Fabry cohort prior to treatment, compared to sex- and age-expected hearing levels and correlating hearing to renal and cerebral findings. Material and methods Retrospective study of baseline hearing status of the Danish Fabry cohort (n = 83, 9-72 years). Air conduction and speech discrimination scores were assessed at 6 frequencies between 0.25-8 kHz bilaterally. Data were collected between 2001-2014 and compiled in STATA using multilinear mixed modelling for statistical evaluation. Results Hearing thresholds at all frequencies deviated from the expected thresholds of an otologically normal cohort (p<0.001) and ranged 0.5 to 1.5 standard deviations below expected values. In total 29 males and 54 females were included. Hearing loss was more pronounced in the higher frequencies. There was a trend of association between hearing loss and measured glomerular filtration rate (mGFR) (p = 0.084). No association was present between hearing loss and albuminuria (p = 0.90), Fabry related cerebral abnormalities (p = 0.84) and cardiac left ventricular mass index, (LVMi) (p = 0.67) independent of sex. Hearing thresholds were poorer for men compared to women (p = 0.001). Sex differences were present at 0.25, 4 and 8 kHz. Conclusion Our findings demonstrated significant hearing loss in Danish FD patients before treatment initiation, being more profound than in otologically healthy individuals at all frequencies. Additionally, we observed no association between hearing loss and LVMi, albuminuria or FD cerebral abnormalities, with a trend of association to mGFR. Synopsis Patients with Fabrys disease have hearing loss of all frequencies and most prominently at high frequencies (4-8 kHz), with no association between the hearing loss and cerebral abnormalities, and cardiac mass but with a trend of association to measured glomerular filtration rate.",
author = "Yazdanfard, {Puriya Daniel} and Madsen, {Christoffer Valdorff} and Nielsen, {Lars Holme} and Rasmussen, {{\AA}se Krogh} and Petersen, {J{\o}rgen Holm} and Alka Seth and S{\o}rensen, {S{\o}ren Schwartz} and Lars K{\o}ber and Ulla Feldt-Rasmussen",
year = "2019",
month = dec,
doi = "10.1371/journal.pone.0225071",
language = "English",
volume = "14",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

RIS

TY - JOUR

T1 - Significant hearing loss in Fabry disease

T2 - Study of the Danish nationwide cohort prior to treatment

AU - Yazdanfard, Puriya Daniel

AU - Madsen, Christoffer Valdorff

AU - Nielsen, Lars Holme

AU - Rasmussen, Åse Krogh

AU - Petersen, Jørgen Holm

AU - Seth, Alka

AU - Sørensen, Søren Schwartz

AU - Køber, Lars

AU - Feldt-Rasmussen, Ulla

PY - 2019/12

Y1 - 2019/12

N2 - Background Fabry disease (FD) is a lysosomal storage disorder resulting in systemic accumulation of globotriaosylceramide resulting in multi-organ dysfunction e.g. cerebral, cardiac, renal and audiologic complications. The audiologic involvement in FD has often been neglected; while not a lethal aspect of the disease, hearing loss can have a significantly negative impact on quality of life. Objectives To investigate baseline hearing status of the Danish Fabry cohort prior to treatment, compared to sex- and age-expected hearing levels and correlating hearing to renal and cerebral findings. Material and methods Retrospective study of baseline hearing status of the Danish Fabry cohort (n = 83, 9-72 years). Air conduction and speech discrimination scores were assessed at 6 frequencies between 0.25-8 kHz bilaterally. Data were collected between 2001-2014 and compiled in STATA using multilinear mixed modelling for statistical evaluation. Results Hearing thresholds at all frequencies deviated from the expected thresholds of an otologically normal cohort (p<0.001) and ranged 0.5 to 1.5 standard deviations below expected values. In total 29 males and 54 females were included. Hearing loss was more pronounced in the higher frequencies. There was a trend of association between hearing loss and measured glomerular filtration rate (mGFR) (p = 0.084). No association was present between hearing loss and albuminuria (p = 0.90), Fabry related cerebral abnormalities (p = 0.84) and cardiac left ventricular mass index, (LVMi) (p = 0.67) independent of sex. Hearing thresholds were poorer for men compared to women (p = 0.001). Sex differences were present at 0.25, 4 and 8 kHz. Conclusion Our findings demonstrated significant hearing loss in Danish FD patients before treatment initiation, being more profound than in otologically healthy individuals at all frequencies. Additionally, we observed no association between hearing loss and LVMi, albuminuria or FD cerebral abnormalities, with a trend of association to mGFR. Synopsis Patients with Fabrys disease have hearing loss of all frequencies and most prominently at high frequencies (4-8 kHz), with no association between the hearing loss and cerebral abnormalities, and cardiac mass but with a trend of association to measured glomerular filtration rate.

AB - Background Fabry disease (FD) is a lysosomal storage disorder resulting in systemic accumulation of globotriaosylceramide resulting in multi-organ dysfunction e.g. cerebral, cardiac, renal and audiologic complications. The audiologic involvement in FD has often been neglected; while not a lethal aspect of the disease, hearing loss can have a significantly negative impact on quality of life. Objectives To investigate baseline hearing status of the Danish Fabry cohort prior to treatment, compared to sex- and age-expected hearing levels and correlating hearing to renal and cerebral findings. Material and methods Retrospective study of baseline hearing status of the Danish Fabry cohort (n = 83, 9-72 years). Air conduction and speech discrimination scores were assessed at 6 frequencies between 0.25-8 kHz bilaterally. Data were collected between 2001-2014 and compiled in STATA using multilinear mixed modelling for statistical evaluation. Results Hearing thresholds at all frequencies deviated from the expected thresholds of an otologically normal cohort (p<0.001) and ranged 0.5 to 1.5 standard deviations below expected values. In total 29 males and 54 females were included. Hearing loss was more pronounced in the higher frequencies. There was a trend of association between hearing loss and measured glomerular filtration rate (mGFR) (p = 0.084). No association was present between hearing loss and albuminuria (p = 0.90), Fabry related cerebral abnormalities (p = 0.84) and cardiac left ventricular mass index, (LVMi) (p = 0.67) independent of sex. Hearing thresholds were poorer for men compared to women (p = 0.001). Sex differences were present at 0.25, 4 and 8 kHz. Conclusion Our findings demonstrated significant hearing loss in Danish FD patients before treatment initiation, being more profound than in otologically healthy individuals at all frequencies. Additionally, we observed no association between hearing loss and LVMi, albuminuria or FD cerebral abnormalities, with a trend of association to mGFR. Synopsis Patients with Fabrys disease have hearing loss of all frequencies and most prominently at high frequencies (4-8 kHz), with no association between the hearing loss and cerebral abnormalities, and cardiac mass but with a trend of association to measured glomerular filtration rate.

U2 - 10.1371/journal.pone.0225071

DO - 10.1371/journal.pone.0225071

M3 - Journal article

C2 - 31809513

AN - SCOPUS:85076272697

VL - 14

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 12

M1 - e0225071

ER -

ID: 241423305